Hematologic Oncology | Specialty

2015 EHA Congress Highlights

June 18th 2015

Interim FDG-PET Scans Enable Response-Adapted Therapy in Hodgkin Lymphoma

June 18th 2015

Interim PET-CT scanning was successfully used to adapt treatment regimens in patients with advanced classical Hodgkin lymphoma.

IDH Inhibition Shows Promise in Two Early Phase AML Studies

June 15th 2015

The IDH1 inhibitor AG-120 and the IDH2 inhibitor AG-221 have demonstrated promising outcomes in patients with hematologic malignancies, including those with acute myeloid leukemia in two separate phase I clinical trials.

Inotuzumab Ozogamicin Shows High MRD-negative CR Rate in ALL

June 14th 2015

Treatment with inotuzumab ozogamicin demonstrated a complete response (CR) or CR with incomplete platelet recovery rate of 80.7% in patients with relapsed or refractory acute lymphoblastic leukemia.

Dr. Jurcic on Lintuzumab and Low-Dose Cytarabine for AML

June 11th 2015

Joseph Jurcic, MD, professor of Clinical Medicine, director of the Hematologic Malignancies Section of the Hematology/Oncology Division, Columbia University Medical Center, discusses a phase I trial of lintuzumab and low-dose cytarabine (LDAC) in older patients with untreated acute myeloid leukemia (AML).

Survivors of Childhood Cancers Living Longer Due to Improvements in Care and Follow-up

May 31st 2015

Over the past 30 years, survivors of childhood cancers have become less likely to die of illnesses caused by their treatment, such as new malignancies or cardiac or lung disease.

Dr. Chanan-Khan on Ibruitinib Combined with BR in CLL/SLL

May 30th 2015

Asher A. Chanan-Khan, MD, chair, Hematology/Oncology, Cancer Center, Mayo Clinic, discusses a recent study that examined ibrutinib combined with bendamustine and ritxuimab (BR) in patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).

Ibrutinib Regimen Improves PFS by 80% in Phase III CLL Study

May 30th 2015

Adding ibrutinib to standard bendamustine and rituximab (BR) reduced the risk of disease progression by 80% compared with BR plus placebo in patients with pretreated CLL or SLL.

Deletion 20q in CLL May Represent Disease Progression

May 28th 2015

The identification of a deletion 20q in a patient with chronic lymphocytic leukemia may not indicate they have developed a myelodysplastic syndrome as was previously assumed.

Dr. Wierda on Ibrutinib Resistance in CLL

May 26th 2015

William G. Wierda, MD, PhD, medical director, Leukemia Center, The University of Texas MD Anderson Cancer Center, discusses resistance to ibrutinib in patients with chronic lymphocytic leukemia (CLL).

CTCs Show Promise as Biomarker for Recurrence in DLBCL

May 21st 2015

Patients with diffuse large B-cell lymphoma who developed detectable circulating tumor DNA during surveillance were more than 200 times more likely to have their disease progress than those who did not have detectable ctDNA.

Radford Discusses Future of Novel Therapies in Non-Hodgkin Lymphoma

May 12th 2015

In an interview with OncLive, John Radford, MD, discusses the impact of novel agents in non-Hodgkin lymphoma and what continued research is necessary to overcome treatment challenges.

Dr. Garcia-Manero on Deferasirox in Iron Chelation Therapy for MDS

May 7th 2015

Guillermo Garcia-Manero, MD, chief, Section of Myelodysplastic Syndromes, deputy chair, Translational Research, professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses deferasirox (Exjade) in iron chelation therapy for patients with myelodysplastic syndromes (MDS).

Dr. Townsley on Screening for GATA2 in At-Risk Patients for MDS, AA, and AML

May 6th 2015

Danielle Townsley, MD, staff clinician, Cell Biology Section, National Institutes of Health, discusses a study which examined screening for GATA2 in patients who are at risk for myelodysplastic syndromes (MDS), aplastic anemia (AA), and acute myeloid leukemia (AML).

Somatic Mutations Could Predict Response to Hypomethylating Agents in MDS

May 2nd 2015

A biomarker model that incorporates the mutational status of multiple somatic genes could be used to predict response to hypomethylating agents for patients with myelodysplastic syndromes.

IPSS Risk and EPO Levels Predict Response to ESAs in MDS

May 2nd 2015

Serum erythropoietin levels and risk by IPSS were predictive of response to erythropoiesis-stimulating agents in patients with myelodysplastic syndromes.

Dr. Gail Roboz on Molecular Mutations in MDS

May 2nd 2015

Gail J. Roboz, MD, associate professor of Medicine, director, Leukemia Program, Weill Medical College of Cornell University, New York-Presbyterian Hospital, discusses the growing field of molecular mutations in myelodysplastic syndromes (MDS).

Dr. Zeidan on Subsequent MDS in Prostate Cancer Patients After Radiotherapy

May 2nd 2015

Amer Zeidan, MBBS, MHS, assistant professor of Medicine, Hematology, Yale Cancer Center, discusses a population-based study of subsequent myelodysplastic syndromes (MDS) in prostate cancer patients after radiotherapy.

Dr. Nimer on the Biggest Challenges of MDS

May 1st 2015

Stephen D. Nimer, MD, Director, Professor of Medicine, Sylvester Comprehensive Cancer Center discusses the challenges of treating myelodysplastic syndromes (MDS).

T-Cell Depleted Allografts Lessen GVHD in MDS

May 1st 2015

Treatment with T-cell depleted transplantation was associated with a lower incidence of acute graft versus host disease (GVHD) and a very low incidence of chronic GVHD compared with unmodified allografts in patients with advanced myelodysplastic syndrome.